With rapid discovery of oncogenic deriver genes over the past decade, several tyrosine kinase inhibitors (TKIs) were developed to target the anaplastic lymphoma kinase (ALK) aberration in non-small cell lung cancers (NSCLCs), including first, second and third-generation ALK inhibitors for ALK-rearranged NSCLC treatment. However with recent data published from several clinical trials and retrospective studies investigating the efficacy of these TKIs in ALK-rearranged NSCLC patients, development of renal cysts is a side effect associated with first generation TKI crizotinib; the mechanism for cyst formation, and whether it is a class effect, is unclear. In this review we will summarize published data on development of kidney injury and renal cysts associated with ALK inhibitors with focus on crizotinib-related renal cysts.
DevarakondaSMorgenszternDGovindanR. Genomic alterations in lung adenocarcinoma. Lancet Oncol2015; 16(7): E342–E351.
2.
HallbergBPalmerRH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer2013; 13(10): 685–700.
3.
SoriaJCTanDSWChiariR, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet2017; 389(10072): 917–929.
4.
ShawATKimTMCrinòL, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol2017; 18(7): 874–886.
5.
PetersSCamidgeDRShawAT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. New Engl J Med2017; 377(9): 829–838.
6.
CamidgeDRKimHRAhnMJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol2021; 16(12): 2091–2108.
7.
SchnellPBartlettCHSolomonBJ, et al. Complex renal cysts associated with crizotinib treatment. Cancer Med2015; 4(6): 887–896.
8.
SahuAPrabhashKNoronhaV, et al. Crizotinib: a comprehensive review. South Asian J Cancer2013; 2(2): 91–97.
9.
OuSHIKwakELSiwak-TappC, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol2011; 6(5): 942–946.
10.
BergethonKShawATOuSH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol2012; 30(8): 863–870.
11.
BlackhallFRoss CamidgeDShawAT, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open2017; 2(3): e000219.
12.
ShawATKimDWNakagawaK, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl J Med2013; 368(25): 2385–2394.
13.
SolomonBJMokTKimDW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med2014; 371(23): 2167–2177.
14.
WuYLLuSLuY, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-Positive advanced Non-Small cell lung cancer. J Thorac Oncol2018; 13(10): 1539–1548.
15.
ShawATRielyGJBangYJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol2019; 30(7): 1121–1126.
16.
Moro-SibilotDCozicNPérolM, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol2019; 30(12): 1985–1991.
17.
OuSHI. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther2011; 5: 471–485.
18.
TanWYamazakiSJohnsonTR, et al. Effects of renal function on crizotinib pharmacokinetics: dose recommendations for patients with ALK-positive non-small cell lung cancer. Clin Drug Investig2017; 37(4): 363–373.
19.
ZhouDTanRJLinL, et al. Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int2013; 84(3): 509–520.
20.
QinSTaglientiMCaiL, et al. c-Met and NF-κB-dependent overexpression of wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. J Am Soc Nephrol2012; 23(8): 1309–1318.
21.
LinYTWangYFYangJC, et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol2014; 9(11): 1720–1725.
22.
BosniakMA. The current radiological approach to renal cysts. Radiology1986; 158(1): 1–10.
23.
WeberTM. Sonography of benign renal cystic disease. Radiol Clin North Am2006; 44(6): 777–786.
24.
PrasadSRDalrympleNCSurabhiVR. Cross-sectional imaging evaluation of renal masses. Radiol Clin North Am2008; 46(1): 95–111, vi. vi-vii.
25.
FerreiraAMReisRBKajiwaraPP, et al. MRI evaluation of complex renal cysts using the Bosniak classification: a comparison to CT. Abdom Radiol2016; 41(10): 2011–2019.
26.
CameronLBJiangDHMoodieK, et al. Crizotinib associated renal cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging2017; 17(1): 7.
27.
YaoJHWangASWangXJ, et al. Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation. Onco Targets Ther2019; 12: 4261–4267.
28.
LongoVCatinoAMMontroneM, et al. Development of complex renal cysts during crizotinib treatment and also during alectinib treatment: a possible drug class effect?J Thorac Oncol2019; 14(8): e170–e172.
29.
HalpennyDFMcEvoySLiA, et al. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-incidence, radiological features and clinical characteristics. Lung Cancer2017; 106: 33–36.
30.
OkuboKSatoANakamotoK, et al. Bosniak category III renal cysts caused by crizotinib in an anaplastic lymphoma kinase gene-rearranged non-small cell lung cancer patient. Urology2018; 121: E3–E4.
31.
KlempnerSJAubinGDashA, et al. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist2014; 19(9): 1008–1010.
32.
YangLGuJNiuX. Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma. Cancer Treat Res Commun2021; 27: 100373.
33.
WiestNETzouKSOlsonMT, et al. Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature. Clin Case Rep2021; 9(6): e04278.
34.
ChanWYAngMKTanDS, et al. Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report. Radiol Case Rep2016; 11(3): 245–247.
35.
YoneshimaYOkamotoIArimura-OmoriM, et al. Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement. Investig New Drugs2015; 33(2): 510–512.
36.
GherardiEBirchmeierWBirchmeierC, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer2012; 12(2): 89–103.
37.
KimDWTiseoMAhnMJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol2017; 35(22): 2490–2498.
38.
HuangWSLiuSZouD, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem2016; 59(10): 4948–4964.
39.
IzzedineHBrocheriouIAmouraZ, et al. Acute tubular injury and renal arterial myocyte vacuolization following crizotinib administration. Kidney Int Rep2021; 6(2): 526–528.
40.
BrosnanEMWeickhardtAJLuX, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer2014; 120(5): 664–674.
41.
GastaudLAmbrosettiDOttoJ, et al. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer2013; 82(2): 362–364.
42.
Martín MartorellPHuerta AlvaroMSolís SalgueroMA, et al. Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer2014; 84(3): 310–313.
43.
YasumaTKobayashiTD’Alessandro-GabazzaCN, et al. Renal injury during long-term crizotinib therapy. Int J Mol Sci2018; 19(10): 2902.
44.
ToyokawaGSetoT. Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat2015; 38(6): 291–298.
45.
WeickhardtAJRothmanMSSalian-MehtaS, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer2012; 118(21): 5302–5309.
46.
CowleyBDJrRuppJCMuesselMJ, et al. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis1997; 29(2): 265–272.
47.
JayapalanSSaboorianMHEdmundsJW, et al. High dietary fat intake increases renal cyst disease progression in Han:sprd-cy rats-cy ratundefined. J Nutr2000; 130(9): 2356–2360.
48.
FribouletLLiNKatayamaR, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov2014; 4(6): 662–673.
49.
ShawATKimDWMehraR, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. New Engl J Med2014; 370(13): 1189–1197.
50.
CrinòLAhnMJDe MarinisF, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol2016; 34(24): 2866–2873.
51.
NishioMFelipEOrlovS, et al. Final overall survival and other efficacy and safety results from ASCEND-3: phase II study of ceritinib in ALKi-Naive patients with ALK-rearranged NSCLC. J Thorac Oncol2020; 15(4): 609–617.
52.
KiuraKImamuraFKagamuH, et al. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Jpn J Clin Oncol2018; 48(4): 367–375.
53.
HongYPassosVQHuangP-H, et al. Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase. J Clin Pharmacol2017; 57(5): 652–662.
54.
CadranelJCortotABLenaH, et al. Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients. ERJ Open Res2018; 4(1): 00058-2017.
55.
IzzedineHEl-FekihRKPerazellaMA. The renal effects of ALK inhibitors. Investig New Drugs2016; 34(5): 643–649.
56.
SetoTKiuraKNishioM, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol2013; 14(7): 590–598.
57.
YangJCOuSIDe PetrisL, et al. Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer. J Thorac Oncol2017; 12(10): 1552–1560.
58.
HidaTNokiharaHKondoM, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet2017; 390(10089): 29–39.
59.
GadgeelSMGandhiLRielyGJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol2014; 15(10): 1119–1128.
60.
MorcosPNYuLBogmanK, et al. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica2017; 47(3): 217–229.
61.
TaimaKTanakaHTanakaY, et al. Regression of crizotinib-associated complex cystic lesions after switching to alectinib. Intern Med2017; 56(17): 2321–2324.
62.
NagaiKOnoHMatsuuraM, et al. Progressive renal insufficiency related to ALK inhibitor, alectinib. Oxf Med Case Reports2018; 2018(4): omy009.
63.
GettingerSNBazhenovaLALangerCJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol2016; 17(12): 1683–1696.
64.
KadiAAAttwaMWDarwishHW. LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways. RSC Adv2018; 8(3): 1182–1190.
65.
ZouHFribouletLKodackD, et al. PF-06463922, an ALK/ros1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell2015; 28(1): 70–81.
66.
ShawATFelipEBauerTM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol2017; 18(12): 1590–1599.
67.
SolomonBJBesseBBauerTM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol2018; 19(12): 1654–1667.
68.
LinSGongJCanasGC, et al. A phase I study to evaluate the pharmacokinetics and safety of lorlatinib in adults with mild, moderate, and severe renal impairment. Eur J Drug Metab Pharmacokinet2022; 47(2): 235–245 (CORRECTION: Eur J Drug Metab Pharmacokinet 2022;47(3):441).
69.
McGeeKStoneNJWadhwaniS, et al. A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy. J Oncol Pharm Pract2021; 27(8): 2010–2013.
70.
BettonMGounantVSannierA, et al. Minimal change disease induced by lorlatinib. J Thorac Oncol2018; 13(8): e154–e156.
